{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-24-000006","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.673065+00:00","generated_at":"2026-06-06T07:26:51.149320+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVS Q4 revenue $93.8B (+11.9% YoY), adj. EPS $2.12; FY2024 adj. EPS guidance cut to $8.30","bullets":["Q4 total revenues $93.8B (+11.9% YoY); GAAP diluted EPS $1.58, adjusted EPS $2.12.","Full-year 2023 revs $357.8B (+10.9%), GAAP EPS $6.47, adj. EPS $8.74; ops cash flow $13.4B.","FY2024 guidance revised: adj. EPS at least $8.30 (from $8.50), GAAP EPS at least $7.06, ops cash flow $12.0B.","Quarterly dividend raised 10% effective Feb 1, 2024; $3.1B returned via dividends in 2023.","Launched CVS CostVantage, Caremark TrueCost pricing models and CVS Healthspire segment for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-24-000006","json":"https://secwatch.observer/filing/0000064803-24-000006.json","markdown":"https://secwatch.observer/filing/0000064803-24-000006.md","text":"https://secwatch.observer/filing/0000064803-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/0000064803-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/cvs-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:26:51.149320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67e48e9fed52736d4cc0f98711b097fef53ade2c","claim":"CVS HEALTH Corp reported three months and year ended December 31, 2023 results: revenue $93.8 billion, EPS GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12. Guidance lowered.","evidence_excerpt":"(NYSE: CVS) today announced operating results for the three months and year ended December 31, 2023. FOURTH QUARTER HIGHLIGHTS KEY FINANCIAL DATA • Total revenues increased to $93.8 billion, up 11.9% compared to prior year • GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12 FULL-YEAR HIGHLIGHTS • Total revenues increased to $357.8 billion, up 10.9% compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480324000006/0000064803-24-000006-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and year ended December 31, 2023"},{"label":"Revenue","value":"$93.8 billion"},{"label":"EPS","value":"GAAP diluted EPS of $1.58 and Adjusted EPS of $2.12"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}